A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates
- 21 January 2005
- journal article
- Published by Wiley in Haemophilia
- Vol. 11 (1), 5-12
- https://doi.org/10.1111/j.1365-2516.2005.01055.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- FDA Workshop on factor VIII inhibitors held at the NIH, Bethesda, MA on 21 November 2003Haemophilia, 2004
- Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patientsSeminars in Hematology, 2001
- Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home TherapyThrombosis and Haemostasis, 2000
- Surveillance for Factor VIII Inhibitor Development in the Canadian Hemophilia A Population Following the Widespread Introduction of Recombinant Factor VIII Replacement TherapyTransfusion Science, 1998
- A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia AThrombosis and Haemostasis, 1997
- A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study GroupBlood, 1993
- Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia ANew England Journal of Medicine, 1990
- The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitorsBlood, 1988